SG
Therapeutic Areas
Unicycive Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Oxylanthanum Carbonate (OLC) | Hyperphosphatemia in Chronic Kidney Disease (CKD) | NDA Submitted |
| UNI-494 | Acute Kidney Injury (AKI) | Preclinical |
Leadership Team at Unicycive Therapeutics
GR
Guru Reddy, Ph.D.
VP, Preclinical R&D
DJ
Douglas Jermasek, M.B.A.
EVP, Corporate Strategy
JT
John Townsend, C.P.A.
Chief Financial Officer
PG
Pramod Gupta, Ph.D.
EVP, Operations
GA
Gaurav Aggarwal, MD
Board of Directors
SK
Sara Kenkare-Mitra, Ph.D.
Board of Directors
S"
Sandeep "Steve" Laumas, MD
Board of Directors
MW
Myles Wolf, MD, M.M.Sc.
Scientific Board of Directors
PE
Pablo E. Pergola, MD, Ph.D.
Scientific Board of Directors
GM
Glenn M. Chertow, MD, M.P.H.
Scientific Board of Directors